Publicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (52)

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia, Vol. 60, pp. S38-S45

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

  2. Cardiorenal benefits of finerenone: protecting kidney and heart

    Annals of Medicine, Vol. 55, Núm. 1, pp. 502-513

  3. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  4. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease

    Nefrologia, Vol. 43, Núm. 4, pp. 386-398

  5. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

  6. Quantitative proteomics in medication-related osteonecrosis of the jaw: A proof-of-concept study

    Oral Diseases, Vol. 29, Núm. 5, pp. 2117-2129

  7. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study

    Future oncology (London, England), Vol. 18, Núm. 35, pp. 3913-3927

  3. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  4. Representativeness of the Spanish Thoracic Tumour Registry. Comparison of sociodemographic data with other national registries

    Gaceta Sanitaria, Vol. 36, Núm. 6, pp. 540-545

  5. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study

    Translational Lung Cancer Research, Vol. 10, Núm. 10, pp. 3902-3911

  2. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169

  3. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  4. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

    Gynecologic Oncology, Vol. 161, Núm. 3, pp. 681-686

  5. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

  6. “I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

    Culture, Health and Sexuality, Vol. 23, Núm. 8, pp. 1066-1078

2020

  1. Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

    Cells, Vol. 9, Núm. 2